Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Oncolytic viruses as therapeutic cancer vaccines

Bartlett, DL and Liu, Z and Sathaiah, M and Ravindranathan, R and Guo, Z and He, Y and Guo, ZS (2013) Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer, 12 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (683kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop, genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in both animal models and human patients. Combination with other immunotherapy regimens improve overall therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index. Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines. © 2013 Bartlett et al.; licensee BioMed Central Ltd.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Bartlett, DLdlb3@pitt.eduDLB3
Liu, Zzul2@pitt.eduZUL2
Sathaiah, M
Ravindranathan, R
Guo, Z
He, Y
Guo, ZSzsg2@pitt.eduZSG2
Centers: Other Centers, Institutes, or Units > Pittsburgh Cancer Institute
Date: 11 September 2013
Date Type: Publication
Journal or Publication Title: Molecular Cancer
Volume: 12
Number: 1
DOI or Unique Handle: 10.1186/1476-4598-12-103
Schools and Programs: School of Medicine > Surgery
Refereed: Yes
Article Type: Review
Date Deposited: 02 Dec 2016 16:07
Last Modified: 15 Jun 2019 09:55
URI: http://d-scholarship.pitt.edu/id/eprint/29680

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item